Celsion Corp.’s (CLSN) “Buy” Rating Reiterated at Maxim Group
Separately, HC Wainwright reaffirmed a buy rating and issued a $3.00 price objective on shares of Celsion Corp. in a research note on Tuesday, July 12th.
Shares of Celsion Corp. (NASDAQ:CLSN) opened at 1.22 on Thursday. Celsion Corp. has a 12-month low of $1.04 and a 12-month high of $2.31. The company has a 50-day moving average price of $1.24 and a 200-day moving average price of $1.36. The firm’s market capitalization is $31.49 million.
Celsion Corp. (NASDAQ:CLSN) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.02. Celsion Corp. had a negative return on equity of 103.07% and a negative net margin of 3,966.14%. Equities analysts predict that Celsion Corp. will post ($0.83) EPS for the current year.
A hedge fund recently bought a new stake in Celsion Corp. stock. Seizert Capital Partners LLC purchased a new position in shares of Celsion Corp. (NASDAQ:CLSN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 120,022 shares of the company’s stock, valued at approximately $152,000. Seizert Capital Partners LLC owned 0.51% of Celsion Corp. at the end of the most recent quarter. 15.19% of the stock is owned by institutional investors and hedge funds.
About Celsion Corp.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.